Liver neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
mTORSTAT3 expression in hepatoma cells HepG2 was significantly higher than that in normal liver cells. mTOR blocking can reduce the expression of STAT3, which is also closely related to the invasion and metastasis of liver cancer cells.
|
25063062 |
2014 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Antitumor progression potential of morusin suppressing STAT3 and NFκB in human hepatoma SK-Hep1 cells.
|
25476160 |
2015 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
One of 3 candidate genes, Stat3, displayed dose-dependent DNA methylation changes in both 10-month mice with liver tumors as compared to those without liver tumors and 3-week sibling mice from the same exposure study, implicating Stat3 as a potential epigenetic biomarker of both early life BPA exposure and adult disease in mice.
|
26542749 |
2015 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
STAT-3 is active during the regenerative growth of the liver, but there are hardly any data about its presence in liver tumours.
|
12957465 |
2003 |
Liver neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression.
|
27553854 |
2016 |
Liver neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Interleukin-6 (IL-6) causes the rapid activation of the acute-phase response factor (APRF) in the liver of animals during acute inflammation and in cultured human hepatoma cells (HepG2) and induces the transcription of the acute-phase protein genes, e.g. alpha 2-macroglobulin (alpha 2-M).
|
7519723 |
1994 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TTF1, in the Form of Nanoparticles, Inhibits Angiogenesis, Cell Migration and Cell Invasion In Vitro and In Vivo in Human Hepatoma through STAT3 Regulation.
|
27834930 |
2016 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Functional genomics identifies hepatitis-induced STAT3-TYRO3-STAT3 signaling as a potential therapeutic target of hepatoma.
|
31831556 |
2020 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines.
|
9647240 |
1998 |
Liver neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here we demonstrate that long-term (3-6 days) but not short-term (up to 1 day) IFN-gamma treatment of human hepatoma Hep3B cells attenuates IFN-alpha activation of STAT1 (signal transducers and activators of transcription factor 1), STAT2 and STAT3, but enhances IFN-gamma and interleukin 6 activation of STATs.
|
14690454 |
2004 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
|
30158673 |
2019 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results showed a cross-talk between cyclic-AMP and JAK/STAT pathways in liver tumors and they reinforce the role of STAT3 activation in liver tumorigenesis.
|
21835143 |
2012 |
Liver neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In summary, activation of hepatic AMPK/sirtuin-1 and FGF21/β-klotho signaling pathways combined with down-regulation of STAT3/NFκB-mediated inflammatory and tumorigenic signaling pathways can explain the absence of hepatic tumors in AAV-NT mice.
|
28334808 |
2017 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
|
29115974 |
2017 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate that PML modulates IL-6-induced STAT3 activation and hepatoma cell growth by interacting with HDAC3.
|
25892518 |
2015 |
Liver neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Constitutively activated STAT3 plays a pivotal role in holding cancer stemness of HCC CSCs, which are essential for hepatoma initiation, relapse, metastasis and drug resistance.
|
30709346 |
2019 |